NCT06886126View on ClinicalTrials.gov

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

September 23, 2025

Study Completion Date

November 30, 2025

Conditions
Obesity
Interventions
DRUG

HDM1005 injection or placebo

HDM1005 injection subcutaneous injection QW for 22weeks

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY